>>Kosan Announces Data Presentations at ASCO 2007 Annual Meeting
Wednesday May 23, 4:00 pm ET
HAYWARD, Calif., May 23 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN - News) today announced that data will be presented on the Company's clinical pipeline, including Hsp90 inhibitors tanespimycin and alvespimycin, and epothilone KOS-1584, at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO), being held at McCormick Place, Chicago, IL, June 1-5, 2007.
Poster presentations on Kosan's programs are as follows.
Date Abst Title Session/Location Author
No. Poster Number
Saturday 1115 Phase 1 trial of Breast Cancer Kathy Miller, MD
6/2 alvespimycin General Poster
2:00-6:00 (KOS-1022; 17-DMAG) S Hall A2
and trastuzumab Number P2
Sunday 8558 Phase 2 trial of Melanoma Richard Kefford, MD
6/3 tanespimycin General Poster
2:00-6:00 (KOS-953), S Hall A2
a heat shock Number R3
protein 90 (Hsp90)
inhibitor in patients
with metastatic
melanoma
Saturday 3532 Tanespimycin (T)+ Developmental Paul Richardson, MD
6/2 Bortezomib (BZ) Therapeutics
2:00-6:00; in multiple myeloma Poster
5:00-6:00 (MM): pharmacology, Presentation:
safety and activity Room S102a,
on relapsed/ Number 3;
refractory Discussion: Room
(rel/ref) S100a
patients
Sunday 2571 Phase 1 trial Developmental Alison Stopek, MD
6/3 of KOS-1584 Therapeutics
8:00-12:00 (a novel epothilone) General Poster
using two weekly S Hall A2
dosing schedules Number C13
About Kosan
Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.
Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade® (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin® (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.
Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.
For additional information on Kosan Biosciences, please visit the company's website at kosan.com. <<
snip
Cheers, Tuck |
